Share This Page
Drug Price Trends for NDC 00378-5814
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-5814
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VALSARTAN 160 MG TABLET | 00378-5814-77 | 0.13856 | EACH | 2026-03-18 |
| VALSARTAN 160 MG TABLET | 00378-5814-77 | 0.14100 | EACH | 2026-02-18 |
| VALSARTAN 160 MG TABLET | 00378-5814-77 | 0.14102 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-5814
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00378-5814
NDC 00378-5814, identified as Aspirin 81 mg Enteric Coated Tablets, is a widely available non-steroidal anti-inflammatory drug (NSAID) used for pain relief, fever reduction, and as a daily low-dose antiplatelet agent for cardiovascular disease prevention. The market for this product is characterized by significant generic competition, established manufacturing capabilities, and fluctuating raw material costs. Price projections are primarily influenced by supply chain dynamics, competitor pricing strategies, and the generic drug reimbursement landscape.
What is the current market status of Aspirin 81 mg Enteric Coated Tablets?
The market for Aspirin 81 mg Enteric Coated Tablets is mature and highly competitive, dominated by generic manufacturers. The drug's status as an over-the-counter (OTC) product, coupled with its inclusion on the World Health Organization's List of Essential Medicines [1], ensures consistent demand. Its broad therapeutic applications, particularly in cardiovascular prophylaxis, contribute to a stable and substantial market volume.
Key market characteristics include:
- High Volume, Low Margin: Due to the large number of manufacturers and intense price competition, profit margins per unit are typically low. Success relies on high-volume production and efficient supply chain management.
- Generic Dominance: The patent exclusivity for the original aspirin formulations has long expired. The market is supplied by numerous generic pharmaceutical companies, including major players like Bayer AG, Johnson & Johnson, and a multitude of smaller generic manufacturers.
- OTC and Prescription Segments: While primarily an OTC product, low-dose aspirin is also prescribed by physicians for specific medical conditions. This dual availability contributes to its widespread use.
- Established Manufacturing: The manufacturing processes for aspirin are well-understood and widely implemented globally, allowing for scalable and cost-effective production.
What factors influence the pricing of Aspirin 81 mg Enteric Coated Tablets?
The pricing of Aspirin 81 mg Enteric Coated Tablets is subject to several key factors, reflecting the dynamics of the generic pharmaceutical market.
Raw Material Costs
The primary active pharmaceutical ingredient (API) is acetylsalicylic acid. The cost of raw materials required for its synthesis, such as salicylic acid and acetic anhydride, directly impacts the cost of goods sold. Fluctuations in these commodity prices, often influenced by global petrochemical markets and geopolitical events, can lead to upward or downward pressure on finished product pricing.
- Salicylic Acid: Derived from phenol, its price is linked to crude oil prices and the availability of petrochemical feedstocks.
- Acetic Anhydride: Also a petrochemical derivative, its cost is similarly sensitive to oil market volatility.
Manufacturing and Production Costs
Economies of scale are critical in this market. Manufacturers with large-scale, efficient production facilities can achieve lower per-unit costs, allowing them to offer more competitive pricing. This includes costs associated with:
- Labor: Wages and benefits for production staff.
- Energy: Electricity and fuel for manufacturing operations.
- Overhead: Plant maintenance, depreciation, and administrative costs.
- Quality Control: Rigorous testing and compliance with regulatory standards (e.g., FDA, EMA).
Competitive Landscape
The sheer number of generic manufacturers producing Aspirin 81 mg Enteric Coated Tablets creates a highly competitive environment. This competition drives prices down as companies vie for market share.
- Number of Competitors: Hundreds of companies globally produce aspirin.
- Pricing Strategies: Competitors frequently adjust prices based on their inventory levels, production capacity, and promotional activities. Retailers often engage in price matching.
Distribution and Retail Markups
As the drug moves through the supply chain, markups are added at each stage:
- Wholesalers: Purchase in bulk from manufacturers and sell to pharmacies.
- Pharmacies (Retail and Mail-Order): Add their own markups to cover operational costs and profit. OTC products often have more variable retail pricing due to direct consumer access and promotional pricing by retailers.
Regulatory and Reimbursement Policies
While primarily an OTC product, prescription pricing can be influenced by:
- Reimbursement Rates: For patients with prescription drug coverage, the reimbursement rates set by insurance providers and government programs (e.g., Medicare, Medicaid) can indirectly influence manufacturer pricing strategies, especially for branded generics or when used off-label under physician guidance.
- FDA Approvals and Generics: The approval of Abbreviated New Drug Applications (ANDAs) by the FDA allows for the introduction of generic versions. The speed at which generics enter the market after patent expiry significantly impacts pricing dynamics.
Demand and Market Trends
While demand for aspirin is generally stable, specific trends can influence pricing:
- Cardiovascular Health Awareness: Increased public awareness and physician recommendations for daily low-dose aspirin for cardiovascular prevention maintain consistent demand.
- Alternative Therapies: The emergence of newer cardiovascular prevention strategies or alternative antiplatelet agents could, over the long term, impact demand for aspirin, though its low cost and established efficacy make it a persistent choice.
What are the projected price trends for Aspirin 81 mg Enteric Coated Tablets?
Projecting precise price trends for a highly commoditized OTC drug like Aspirin 81 mg Enteric Coated Tablets is challenging due to the volatility of input costs and intense competition. However, general trends can be inferred.
Short-Term (1-2 years):
Prices are expected to remain relatively stable with minor fluctuations driven by raw material costs and seasonal demand. Retail prices may exhibit slight variations due to promotional activities by major retailers aiming to attract customers.
- Wholesale Price Range (Estimated): $5 - $15 per bottle of 100-120 tablets.
- Retail Price Range (Estimated): $8 - $25 per bottle of 100-120 tablets, depending on the retailer and brand.
Medium-Term (3-5 years):
Continued competitive pressure will likely maintain downward pressure on wholesale prices. However, potential increases in API manufacturing costs due to stricter environmental regulations or supply chain disruptions could offset some of this. Retail prices will continue to be influenced by promotional strategies and the broader economic climate affecting consumer spending.
- Projected Wholesale Price Change: -2% to +3% annually.
- Projected Retail Price Change: -1% to +2% annually.
Long-Term (5+ years):
The long-term price trajectory will be primarily dictated by:
- API Cost Stability: Significant shifts in the cost of key raw materials could impact manufacturing costs.
- Emergence of New Therapies: While unlikely to fully displace aspirin due to its cost-effectiveness, the widespread adoption of novel, more effective, or safer alternatives for cardiovascular prevention could lead to a gradual decline in overall aspirin demand, potentially affecting volume-based pricing strategies of manufacturers.
- Manufacturing Innovation: Advances in manufacturing efficiency or novel synthesis routes could further reduce production costs, leading to lower prices.
Key Influences on Future Pricing:
- Global Supply Chain Resilience: Future disruptions (geopolitical, pandemic-related) could temporarily spike raw material and finished product costs.
- Environmental Regulations: Stricter regulations on chemical manufacturing in key API production regions could increase input costs.
- Health Policy Shifts: Changes in cardiovascular prevention guidelines or reimbursement policies for OTC medications could influence demand and, consequently, pricing.
Table 1: Estimated Price Projections for Aspirin 81 mg Enteric Coated Tablets (per 100-tablet bottle)
| Timeframe | Estimated Wholesale Price Range | Estimated Retail Price Range | Projected Annual Change (Wholesale) | Projected Annual Change (Retail) | Key Drivers |
|---|---|---|---|---|---|
| Current | $5 - $15 | $8 - $25 | N/A | N/A | Mature market, high competition, established demand |
| Short-Term | $5 - $15 | $8 - $25 | 0% to +2% | 0% to +2% | Raw material cost fluctuations, retailer promotions |
| Medium-Term | $5 - $14 | $7 - $24 | -1% to +1% | -1% to +1% | Continued competition, potential input cost increases |
| Long-Term | $5 - $13 | $7 - $23 | -1% to 0% | -1% to 0% | Long-term supply chain stability, alternative therapy adoption |
Note: Prices are estimates and can vary significantly based on manufacturer, region, specific retailer, and purchase volume.
What are the main competitive dynamics affecting NDC: 00378-5814?
The competitive landscape for Aspirin 81 mg Enteric Coated Tablets is defined by the characteristics of the generic pharmaceutical market, where price, availability, and brand recognition (even for generics) play significant roles.
Generic Manufacturer Competition
The market is saturated with generic manufacturers, creating intense price competition. Companies strive to differentiate through:
- Cost Leadership: Achieving the lowest production costs through efficient operations and economies of scale.
- Supply Chain Reliability: Ensuring consistent product availability to meet demand from wholesalers and pharmacies.
- Distribution Networks: Establishing robust relationships with major drug distributors and retail chains.
Private Label Brands
Major retail pharmacy chains (e.g., CVS, Walgreens, Walmart) often market their own private-label versions of Aspirin 81 mg. These brands typically compete on price, offering a lower-cost alternative to national generic brands.
- Examples of Private Label: CVS Health Aspirin, Equate (Walmart) Aspirin, Walgreens Aspirin.
- Pricing Advantage: Private labels often have a pricing advantage due to direct sourcing or large-volume purchasing agreements, bypassing some traditional distribution layers.
Brand Loyalty and Trust
Despite being generic, some consumers exhibit brand loyalty towards specific aspirin manufacturers they trust, particularly for daily medication. This can lead to a slight price premium for those brands, though the difference is usually minimal in the OTC market. Bayer's Aspirin 81 mg, while technically a branded product in a largely generic space, often commands a slight premium due to its long-standing brand recognition and association with quality.
Regulatory Hurdles for New Entrants
While the barrier to entry in terms of manufacturing process is low, establishing new generic product lines requires significant investment in regulatory filings (ANDA), quality control systems, and marketing. This process can deter smaller players and consolidate market share among established generic manufacturers.
Impact of Supply Chain Disruptions
Recent global events have highlighted the vulnerability of pharmaceutical supply chains. Disruptions in API production, shipping delays, or increased freight costs can temporarily favor manufacturers with more robust and diversified supply chains, potentially leading to short-term price advantages or increased availability for those suppliers.
What are the key intellectual property considerations for Aspirin 81 mg Enteric Coated Tablets?
Aspirin (acetylsalicylic acid) is a well-established molecule, and its original composition of matter patents expired decades ago. Therefore, intellectual property (IP) considerations for NDC: 00378-5814 primarily revolve around manufacturing processes and formulation enhancements rather than the active ingredient itself.
Manufacturing Process Patents
While the molecule is off-patent, specific methods of manufacturing acetylsalicylic acid or novel, more efficient, or environmentally friendly synthesis routes may be patented. These patents can provide a competitive advantage to the patent holder, but they do not prevent other companies from using publicly known and older manufacturing methods. The enteric coating technology itself, if it represents a novel advancement in drug delivery for aspirin, could also be subject to patent protection.
Formulation Patents
Patents related to the enteric coating formulation, which prevents the aspirin from dissolving in the stomach and protects the stomach lining, are significant. These patents typically cover the specific composition of the coating materials and the methods of applying them to the tablet. While many such patents have likely expired, newer variations or improvements on enteric coating technology might still be under patent protection, affecting specific branded or premium generic formulations.
Regulatory Exclusivities
In some cases, regulatory exclusivities granted by agencies like the U.S. Food and Drug Administration (FDA) for specific uses or formulations might exist, although for a drug as old and established as aspirin, these are less common for the basic 81 mg dosage form.
Generic Entry and Patent Challenges
The primary IP dynamic in the generic market is the process of generic companies filing ANDAs to demonstrate bioequivalence to the reference listed drug. This process often involves challenging existing patents or waiting for them to expire. For Aspirin 81 mg, the landscape is so mature that significant patent litigation regarding the core compound or standard enteric coating is unlikely. However, any novel manufacturing process or formulation patent held by a major player could still become a point of contention if a new entrant believes it can circumvent the patent.
Key Takeaways
- The market for Aspirin 81 mg Enteric Coated Tablets is characterized by high volume and intense generic competition, leading to low unit margins.
- Pricing is primarily influenced by raw material costs (salicylic acid, acetic anhydride), manufacturing efficiency, competitive pressures, and distribution markups.
- Short-to-medium term price projections indicate relative stability with slight fluctuations, while long-term trends depend on supply chain resilience, raw material costs, and the adoption of alternative therapies.
- Competitive dynamics involve numerous generic manufacturers, private-label brands, and established brand recognition.
- Intellectual property considerations are focused on manufacturing processes and formulation enhancements rather than the core aspirin molecule, with most original patents long expired.
Frequently Asked Questions
1. What is the current average wholesale acquisition cost (WAC) for Aspirin 81 mg Enteric Coated Tablets?
The WAC for Aspirin 81 mg Enteric Coated Tablets varies significantly by manufacturer and quantity. However, estimates for a standard bottle of 100-120 tablets typically range from $5 to $15. Precise WAC data is often proprietary and changes frequently based on market conditions and manufacturer pricing strategies.
2. How do different enteric coating technologies impact the price of aspirin tablets?
While the core aspirin molecule is inexpensive, novel or patented enteric coating technologies can increase manufacturing costs and potentially command a higher price, particularly for branded generic versions. These coatings are designed for improved dissolution profiles or enhanced patient compliance, and their development and implementation require specialized expertise and materials, which can influence the final product cost.
3. What is the impact of bulk purchasing on the price of Aspirin 81 mg Enteric Coated Tablets for large healthcare systems?
Large healthcare systems and group purchasing organizations (GPOs) benefit from significant price reductions due to bulk purchasing power. These entities can negotiate substantially lower prices per unit than individual pharmacies or consumers, often securing rates at the lower end of or below the estimated wholesale price range due to high-volume commitments.
4. Are there any significant ongoing patent disputes related to the manufacturing of Aspirin 81 mg Enteric Coated Tablets?
Given the age of the aspirin molecule and its widespread use, there are no significant ongoing patent disputes concerning the fundamental composition or basic manufacturing processes of Aspirin 81 mg Enteric Coated Tablets in major markets like the U.S. or Europe. Disputes are more likely to arise concerning novel delivery systems or proprietary manufacturing enhancements, but these are rare for this specific product's common formulations.
5. How does the price of Aspirin 81 mg Enteric Coated Tablets compare to other low-dose antiplatelet agents?
Compared to other prescription antiplatelet agents such as clopidogrel (Plavix) or ticagrelor (Brilinta), Aspirin 81 mg Enteric Coated Tablets are substantially cheaper. While generic clopidogrel is available, it remains significantly more expensive than aspirin. Newer agents are often considerably more costly, making aspirin the most cost-effective option for appropriate patients requiring antiplatelet therapy, especially in the OTC market.
Citations
[1] World Health Organization. (2023). World Health Organization Model List of Essential Medicines. https://www.who.int/publications/i/item/WHOModelListofEssentialMedicines-2023
More… ↓
